Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal Polysaccharide vaccine in middle-aged and older adults

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 516-524

  Musher, Daniel M ^a,b   Manoff, Susan B ^c   Liss, Charlie ^c   McFetridge, Richard D ^c   Marchese, Rocio D ^c   Bushneil, Bonnie ^c   Alvarez, Frances ^c   Painter, Carla ^c   Blum, Michael D ^c,d   Silber, Jeffrey L ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PLACEBO; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CHILL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GEOMETRY; GROUPS BY AGE; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNES; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; SEROTYPE; SIDE EFFECT; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLACEBOS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 75749150864     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649839     Document Type: Article

References (32)

1. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneu-mococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980; 303:549-552.
2. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-1460.
3. 3. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755. (Pubitemid 36514705)
4. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneu-monia. Clin Infect Dis 2006;43:1004-1008.
5. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Or-enstein WB, eds. Vaccines. 4th ed. Philadelphia, PA: W B. Saunders, 2003:529-588.
6. Centers for Disease Control and Prevention. Prevention of pneumo-coccal disease: recommendations of the Advisory Committee on Im-munization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8): 1-24.
7. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for pre-venting pneumococcal infection in adults. Cochrane Database Syst Rev 2008:CD000422.
8. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, compli-cations, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006;42:1093-1101.
9. 9. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneu-mococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167:1938-1943. (Pubitemid 47606632)
10. 10. Nichol KL, Baken L, Wuorenma S, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159:2437-2442. (Pubitemid 29526772)
11. 11.MusherDM,LuchiMJ,WatsonDA,HamiltonR,BaughnRE.Pneu- mococcalpolysaccharidevaccineinyoungadultsandolderbronchitics: determinationofIgGresponsesbyELISAandtheeffectofadsorptionofserumwithnon-type- specificcellwallpolysaccharide.JInfectDis1990;161:728-735.(Pubitemid20120232)
12. 12.RubinsJB,PuriAKG,LochJ,CharboneauD,MacDonaldR,OpstadN,etal.Magnitude, duration,quality,andfunctionofpneumococcalvaccineresponsesinelderlyadults. JInfectDis1998;178:431-440.(Pubitemid28347925)
13. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avid-ity. Clin Infect Dis 1999;29:281-288.
14. 14.SimberkoffMS,CrossAP,Al-IbrahimM,etal.Efficacyofpneumo- coccalvaccineinhigh-riskpatients: resultsofaVeteransAdministrationcooperativestudy.NEnglJMed1986;315:1318-1327. (Pubitemid17030409)
15. Safdar A, Rodriquez GH, Rueda AA, et al. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia. Cancer 2008; 113:383-387.
16. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; CD000422
17. 17. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneu-mococcal polysaccharide vaccines in adults: a systematic review of ob-servational studies and comparison with results from randomised con-trolled trials. Vaccine 2004;22:3214-3224. (Pubitemid 39037227)
18. Lipsky BA, Hirschmann JV Pneumococcal polysaccharide vaccines do not protect the elderly from pneumococcal infections. Neth J Med 2004; 62:33-35.
19. 19.SankilampiU,HonkanenPO,BloiguA,LeinonenM.Persistenceofantibodies- pneumococcalcapsularpolysaccharidevaccineintheelderly.JInfectDis1997;176: 1100-1104.(Pubitemid27411061)
20. 20. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103. (Pubitemid 37357156)
21. 21. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-248. (Pubitemid 29058113)
22. Heidelberger M, DiLapi MM, Siegel M, Walter AW Persistence of antibodies in human subjects injected with pneumococcal polysac-charides. J Immunol 1950;65:535-541.
23. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneu-mococcal conjugate and polysaccharide vaccines: is hyporesponsive-ness as issue? Lancet Infect Dis 2007;7(9):597-606.
24. 24. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immuno-sorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003; 10:514-519. (Pubitemid 36890430)
25. 25. Marchese RD, Jain NT, Antonello J, et al. Enzyme-linked immuno-sorbent assay for measuring antibodies to pneumococcal polysaccha-rides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assay. Clin Vaccine Immunol 2006; 13:905-912. (Pubitemid 44409630)
26. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-226.
27. Musher DM, Groover JE, Watson DA, et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular poly-saccharides. J Investig Med 1997; 45:57-68.
28. Heidelberger M, MacLeod CM, diLapi MM. The human antibody re-sponse to simultaneous injection of six specific polysaccharides of pneumococcus. J Exp Med 1948; 88:369-372.
29. 29.HeilmannC.Vaccination- inducedactivationofhumanbloodTcellssuppressingpneumococcalpolysaccharide- specificBcells.ActaPatholMicrobiolImmunolScandC1987;95:65-69.(Pubitemid17079468)
30. Musher DM, Rueda AJ, Graviss EA, Rodriguez-Barradas M. Response to pneumococcal polysaccharide and protein-conjugate vaccines singly or sequentially in adults who have recovered from pneumococcal pneu-monia. J Infect Dis 2008; 198:1019-1027.
31. 31. Musher DM, Phan HM, Watson DA, Baughn RE. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital ad- mission for Pneumococcal pneumonia. J Infect Dis 2000; 182:158-167. (Pubitemid 30497800)
32. Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≥65 years. J Infect Dis 2010;201:525-533 (in this issue).